Replies to post #710918 on NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

exwannabe,

You just answered your own question. Price is the consideration for NICE not MHRA!; ). NICE can give a final appraisal determination that gives access to the set asides without a final fixed price agreement in place until a later date even though they are set up now to have reimbursement align more closely to MAA approval. The final fixed price will likely be tied into actual costs involved with the set up of Flaskworks and any costs associated with any changing regulations centered around this new tech. Best wishes.

[Nemesis18]

You and others may recall, that from the moment I joined this forum, I stated that there wasn't a hope in hell of the NICE ever making DCVAx-L a prescriptive treatment, and that NWBO would fail to meet the very high bar set for a proposed NHS supplier of new cancer treatments.
The price point to benefit ratio is also so far below what is needed to demand £250,000 a pop from NHS Funds, it would have been a waste of time to even start the pricing / costing application.

And this is even before all efficacy issues are settled by the MHRA & external Investigators (Upto and including some breaches of the existing manufacturing licences.)

With all this uncertainty now being reflected in the SP and other trading restrictions.

Finally, NHS England dies NOT exist for you all to get get rich from you gamble.

As with me, NHS Governance to there to protect both the financial health/ well being of both itself and its patients